Just recently, nearly 40 years after this discovery, sacituzumab govitecan, a Trop2-targeting antibody drug conjugate, has been granted an accelerated approval for therapy of metastatic triple-negative breast cancer, opening a new chapter of such successful story. The gene discussed is TACSTD2; the disease is triple-negative breast carcinoma.